Overweight or Obesity, OSA (Obstructive Sleep Apnea) research hub

J5P-MC-GZRA: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (ATTAIN-OSA); J5P-MC-GZ01: Participants with OSA unable or unwilling to use PAP therapy; J5P-MC-GZ02: Participants with OSA on PAP therapy

This study is testing a once-daily tablet called orforglipron for adults living with overweight or obesity and obstructive sleep apnoea. Researchers want to see if the medicine helps improve night-time breathing over 52 weeks compared to a dummy pill (placebo).